SRR12696793
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.400
- MYC_TARGETS_V2+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- CHOLESTEROL_HOMEOSTASIS+0.300
- DNA_REPAIR+0.300
- HYPOXIA+0.300
- MITOTIC_SPINDLE+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
Top 10 suppressed
- BILE_ACID_METABOLISM-0.300
- ALLOGRAFT_REJECTION-0.200
- ESTROGEN_RESPONSE_LATE-0.200
- INFLAMMATORY_RESPONSE-0.200
- KRAS_SIGNALING_DN-0.200
- APICAL_SURFACE-0.100
- COMPLEMENT-0.100
- FATTY_ACID_METABOLISM-0.100
- KRAS_SIGNALING_UP-0.100
- SPERMATOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696801 | — | — | 0.886 |
| 2 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.862 |
| 3 | SRR934935 | — | — | 0.856 |
| 4 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.855 |
| 5 | SRR934967 | — | — | 0.854 |
| 6 | 5E729BD1-654D-4334-A80F-3EDD472551B4 | — | — | 0.853 |
| 7 | MNG296 | — | — | 0.842 |
| 8 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.835 |
| 9 | SRR934817 | — | — | 0.833 |
| 10 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |